{
  "id": "1a8a4fec-7883-4a52-86f2-2fb8c2c847a5",
  "title": "Hims \u0026 Hers projects Q1 2025 revenue of $520M-$540M with expanded weight loss offerings",
  "link": "https://seekingalpha.com/news/4412904-hims-and-hers-projects-q1-2025-revenue-of-520m-540m-with-expanded-weight-loss-offerings?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Mon, 24 Feb 2025 19:43:43 -0500",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "hims",
    "hims.ws"
  ],
  "byline": "SA Transcript Insights Editor",
  "length": 1053,
  "excerpt": "Discover how Hims \u0026 Hers Health closed 2024 with strong growth, expanding weight-loss solutions, and innovation-focused investments in personalized...",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "Earnings Call Insights: Hims \u0026 Hers Health, Inc. (NYSE:HIMS) Q4 2024 Management View CEO Andrew Dudum highlighted the company's advancements toward its vision of on-demand, personalized healthcare, noting the integration of lab testing capabilities and the acquisition of a peptide facility to Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.",
  "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003c/header\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cp\u003eEarnings Call Insights: Hims \u0026amp; Hers Health, Inc. (\u003cspan\u003eNYSE:\u003ca href=\"https://seekingalpha.com/symbol/HIMS\" title=\"Hims \u0026amp; Hers Health, Inc.\"\u003eHIMS\u003c/a\u003e\u003c/span\u003e) Q4 2024\u003c/p\u003e \u003ch3\u003eManagement View\u003c/h3\u003e \u003cul\u003e \u003cli\u003eCEO Andrew Dudum highlighted the company\u0026#39;s advancements toward its vision of on-demand, personalized healthcare, noting the integration of lab testing capabilities and the acquisition of a peptide facility to\u003c/li\u003e \u003c/ul\u003e\u003c/div\u003e\u003cp\u003e\u003cstrong\u003eSeeking Alpha\u0026#39;s Disclaimer: \u003c/strong\u003eThe earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts \u003ca href=\"https://seekingalpha.com/symbol/HIMS/earnings/transcripts\"\u003ehere\u003c/a\u003e. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "2 min read",
  "publishedTime": "2025-02-25T00:43:43Z",
  "modifiedTime": null
}
